Company news

Gyre Therapeutics, Inc. news in 2025

Gyre Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update

November 6, 2025

Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis

October 14, 2025

Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025

October 13, 2025

Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

September 4, 2025

Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors

August 21, 2025

Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update

August 10, 2025

Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China

June 9, 2025

Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

May 28, 2025

Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China

May 21, 2025

Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

May 21, 2025

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock

May 21, 2025

Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025

Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications

March 30, 2025

Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology

March 26, 2025

Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 16, 2025

Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors

January 5, 2025

Decks in 2025